Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML ; volume:103 ; number:6 ; day:18 ; month:4 ; year:2024 ; pages:1941-1945 ; date:6.2024
Annals of hematology ; 103, Heft 6 (18.4.2024), 1941-1945, 6.2024
- Urheber
-
Jain, Akriti G.
Gesiotto, Quinto
Ball, Somedeb
Nodzon, Lisa
Rodriguez, Amanda
Chan, Onyee
Padron, Eric
Kuykendall, Andrew
Komrokji, Rami
Sallman, David A.
Lancet, Jeffrey E.
Pinilla-Ibarz, Javier
Sweet, Kendra
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-024-05760-6
- URN
-
urn:nbn:de:101:1-2407222101032.190358485304
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jain, Akriti G.
- Gesiotto, Quinto
- Ball, Somedeb
- Nodzon, Lisa
- Rodriguez, Amanda
- Chan, Onyee
- Padron, Eric
- Kuykendall, Andrew
- Komrokji, Rami
- Sallman, David A.
- Lancet, Jeffrey E.
- Pinilla-Ibarz, Javier
- Sweet, Kendra
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
BCAT1 contributes to the development of TKI-resistant CML
Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib
Unilateral Interstitial Lung Disease with Contralateral Effusion: Unusual Case Report of Dasatinib Toxicity
New dosing schedules of dasatinib for CML and adverse event management
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Exacerbation of pleural effusion in a dasatinib-treated patient during the perioperative period
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
BCAT1 contributes to the development of TKI-resistant CML
Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib
Unilateral Interstitial Lung Disease with Contralateral Effusion: Unusual Case Report of Dasatinib Toxicity
New dosing schedules of dasatinib for CML and adverse event management
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Exacerbation of pleural effusion in a dasatinib-treated patient during the perioperative period
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
BCAT1 contributes to the development of TKI-resistant CML
Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib
Unilateral Interstitial Lung Disease with Contralateral Effusion: Unusual Case Report of Dasatinib Toxicity
New dosing schedules of dasatinib for CML and adverse event management
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Exacerbation of pleural effusion in a dasatinib-treated patient during the perioperative period
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance